St. Jude Agrees to Pay $27 Million to Settle False Claims Act Charges for Selling Defective Heart Devices (Part III of V)

In the third of a series of postings, Michael Volkov reviews a variety of recent FCA cases which demonstrate his point that companies should promptly prepare for an enforcement onslaught over the next few years. St. Jude Medical – acquired by Abbott Laboratories in early 2017 – agreed to pay $27 million to settle charges […]
Must be a Paid Member or a Free Trial Member to Access Content. Members log in here.